Kexing Biopharm's oncology product for international markets, Paclitaxel for Injection (Albumin-Bound) (Apexelsin®), has recently received marketing approval from the Institute of Public Health of Chile (ISP Chile).

Recently, the Key Trademark Protection Committee of the Guangdong Trademark Association officially released the 2025 Guangdong Key Trademark Protection List.

May 19 marks World IBD Day, a global initiative dedicated to raising public awareness of Inflammatory Bowel Disease (IBD) and promoting better disease management and quality of life for patients.

Recently, GB10 Injection, an ophthalmology innovative drug independently developed by Shenzhen Kexing Pharmaceutical Co., Ltd. (a wholly owned subsidiary of Kexing Biopharm), has completed dosing of the first subject in its Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD).

Recently, Kexing Biopharm and Guangzhou Daguang Pharmaceutical officially signed an overseas market cooperation agreement for a portfolio of eye drop products.

Recently, Kexing Biopharm’s overseas anti-tumor product—Paclitaxel for lnjection (Albumin Bound) (Apexelsin®)—has officially obtained marketing authorization from the Emirates Drug Establishment (EDE), entering the core pharmaceutical market of the Middle East.

Recently, both the bevacizumab biosimilar and sorafenib tosylate tablets for overseas markets by Kexing Biopharm have been formally approved for marketing by the Syrian Ministry of Health (MoH).

Paclitaxel for Injection (Albumin-bound) (brand name: Apexelsin®)—has received marketing approval from the Philippine Food and Drug Administration.